睿知中国医院研究地图
候选清单

济南山东第一医科大学

山东省肿瘤医院

Shandong Cancer Hospital and Institute

在本站收录的 53 种疾病中,这家医院列在其中 12 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

山东省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文牵头 2 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma65 篇牵头论文牵头 1 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma59 篇牵头论文牵头 4 项开放试验
  4. 胃癌Stomach cancer33 篇牵头论文牵头 3 项开放试验
  5. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  7. 骨肉瘤Osteosarcoma1 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma4 篇牵头论文
  10. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma4 篇牵头论文
  12. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文

未列出的收录疾病:脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 2220232024: 1120242025: 112025

济南有 2 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-05
    登记号
    NCT07000643

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  2. 正在招募
    Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
    分期
    III期
    开始
    2025-12
    登记号
    NCT07340515

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:山东省肿瘤医院济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术影像与人工智能副作用与生活质量
论文中的科室放疗科
牵头的论文8
  1. Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.2026Oral oncology
  2. A Stacked Multimodality Model Based on Functional MRI Features and Deep Learning Radiomics for Predicting the Early Response to Radiotherapy in Nasopharyngeal Carcinoma.2025Academic radiology
  3. Pretreatment multiparametric MRI radiomics-integrated clinical hematological biomarkers can predict early rapid metastasis in patients with nasopharyngeal carcinoma.2024BMC cancer免费全文
  4. The therapeutic utility of combining dynamic contrast-enhanced magnetic resonance imaging with arterial spin labeling in the staging of nasopharyngeal carcinoma.2023BMC medical imaging免费全文
  5. Association of Socioeconomic Disparities With Nasopharyngeal Carcinoma Survival in an Endemic Area, China.2023Cancer control : journal of the Moffitt Cancer Center免费全文
  6. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes.2022Molecular medicine (Cambridge, Mass.)免费全文
  7. Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.2021BMC cancer免费全文
  8. Dosimetry study of nasopharyngeal carcinoma based on Halcyon accelerator fixed-field intensity-modulated radiation therapy.2021Journal of cancer research and therapeutics
中文论文(未计入)1
  1. [Study on the assignment method of intensity modulated radiotherapy plan for nasopharyngeal carcinoma based on MR images].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma正在招募NCT07000643牵头方(推断)III期2025-05 启动
  2. Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial正在招募NCT07340515牵头方(推断)III期2025-12 启动
  3. A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies状态不明NCT05955105研究中心I/II期2023-07 启动
PubMed 以外找到的论文(未计入)12
  1. Intratumoral metabolic heterogeneity on 18F-FDG PET/CT as a biomarker for tumor staging in nasopharyngeal carcinoma2025Clinical and Translational Imaging论文
  2. Metabolomics and Machine Learning Identify Novel Serum Biomarkers for Nasopharyngeal Carcinoma Diagnosis2025International Journal of Radiation Oncology*Biology*Physics论文
  3. Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.2024Journal of Clinical Oncology会议摘要
  4. Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.2024Journal of Clinical Oncology会议摘要
  5. 32P Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma2023ESMO Open论文
  6. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  7. Feasibility study of pharyngeal constrictor muscle sparing in proton radiotherapy for nasopharyngeal carcinoma based on MRI/CT fusion image2023Research Square预印本
  8. Predicting late radiation-induced xerostomia in nasopharyngeal carcinoma based on radiomics features extracted from T2WI images of parotids2023Radiation Medicine and Protection论文
  9. 1328P Association of socioeconomic disparities with nasopharyngeal carcinoma survival in an endemic area, China2022Annals of Oncology论文
  10. Abstract 5241: p38 MAPK/EGR1/PD-L1 axis promotes radiation resistance of nasopharyngeal carcinoma by enhancing immune evasion2022Cancer Research会议摘要
  11. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  12. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 65 篇,占 2.2%。

牵头论文
65
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 9920222023: 151520232024: 181820242025: 14142025

济南有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 邀请入组
    Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
    分期
    I/II期
    开始
    2024-03
    登记号
    NCT06690216

    年龄 18 岁 至 未注明(登记的条件)

    牵头:山东省肿瘤医院济南

  2. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  3. 正在招募
    A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
    分期
    II期
    开始
    2025-01
    登记号
    NCT06769113

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗新辅助与综合治疗影像与人工智能
论文中的科室放疗科影像/核医学科病理/检验科肿瘤内科
牵头的论文65
  1. 18F-NOTA-FAPI-04 PET/CT metabolic parameters combined with hematological biomarkers predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.2026European journal of nuclear medicine and molecular imaging免费全文
  2. Neoadjuvant tislelizumab with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma.2026International journal of surgery (London, England)
  3. Identifying risk factors and evaluating therapeutic interventions for anastomotic recurrence in postoperative esophageal squamous cell carcinoma.2025BMC cancer免费全文
  4. Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy.2025BMC cancer免费全文
  5. Predicting anastomotic leak in patients with esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy using a nomogram based on CT radiomic and clinicopathologic factors.2025BMC cancer免费全文
  6. Impact of radiation dose to immune cells on survival in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a retrospective analysis.2025BMC cancer免费全文
  7. Dual energy CT-derived quantitative parameters and hematological characteristics predict pathological complete response in neoadjuvant chemoradiotherapy esophageal squamous cell carcinoma patients.2025BMC gastroenterology免费全文
  8. Development and validation a radiomics combined clinical model predicts treatment response for esophageal squamous cell carcinoma patients.2025BMC gastroenterology免费全文
  9. The prognosis prediction value of CD69+ CD8+ tissue-resident memory T cell as a novel indicator of pathologic complete response heterogeneity following different neoadjuvant therapy regimen in esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CII免费全文
  10. Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy.2025Frontiers in immunology免费全文
  11. Tertiary lymphoid structures in esophageal cancer: a novel target for immunotherapy.2025Frontiers in immunology免费全文
  12. Prognostic analysis of esophageal cancer patients after neoadjuvant therapy.2025Frontiers in immunology免费全文
  13. CT-based delta-radiomics nomogram for predicting post-neoadjuvant chemoradiotherapy lymph node metastasis in esophageal squamous cell carcinoma: A feasibility study.2025Journal of cancer research and therapeutics
  14. Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer.2025Journal of cancer research and therapeutics
  15. Multi-task and multi-scale attention network for lymph node metastasis prediction in esophageal cancer.2025Medical & biological engineering & computing
  16. Postoperative Adjuvant Therapy Benefits Non-pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real-World Study.2025Thoracic cancer免费全文
  17. The TDP-43/TP63 Positive Feedback Circuit Promotes Esophageal Squamous Cell Carcinoma Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  18. Neoadjuvant radiation target volume definition in esophageal squamous cell cancer: a multicenter recommendations from Chinese experts.2024BMC cancer免费全文
  19. Association of effective dose to immune cells and vertebral marrow dose with hematologic toxicity during neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.2024BMC cancer免费全文
  20. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.2024BMC cancer免费全文
  21. Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.2024Cancer communications (London, England)RCT免费全文
  22. Single-cell transcriptomic analysis reveals the landscape of epithelial-mesenchymal transition molecular heterogeneity in esophageal squamous cell carcinoma.2024Cancer letters
  23. HRU-Net: A high-resolution convolutional neural network for esophageal cancer radiotherapy target segmentation.2024Computer methods and programs in biomedicine
  24. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.2024Frontiers in immunology免费全文
  25. Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial.2024Future oncology (London, England)RCT免费全文
  26. A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer.2024International journal of radiation oncology, biology, physics
  27. Accurate location describe and management of lymph node recurrence after esophagectomy for thoracic esophageal squamous cell carcinoma: a retrospective cohort study.2024International journal of surgery (London, England)免费全文
  28. [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial.2024Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  29. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.2024Journal of translational medicine免费全文
  30. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients.2024Nutrition (Burbank, Los Angeles County, Calif.)
  31. Comparison of neoadjuvant chemoradiotherapy versus chemoradiotherapy plus immunotherapy for esophageal squamous cell carcinoma in a real-world multicenter cohort: a propensity score matching study.2024Scientific reports免费全文
  32. Assessing the Impact of a 1.5 T Transverse Magnetic Field in Radiotherapy for Esophageal Cancer Patients.2024Technology in cancer research & treatment免费全文
  33. Radiomics-clinical nomogram for preoperative lymph node metastasis prediction in esophageal carcinoma.2024The British journal of radiology免费全文
  34. The role of spleen radiomics model for predicting prognosis in esophageal squamous cell carcinoma patients receiving definitive radiotherapy.2024Thoracic cancer免费全文
  35. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.2023British journal of cancerRCT免费全文
  36. LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma.2023Cancer immunology, immunotherapy : CII免费全文
  37. TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.2023Cancer immunology, immunotherapy : CII免费全文
  38. Progression of precancerous lesions of esophageal squamous cell carcinomas in a high-risk, rural Chinese population.2023Cancer medicine免费全文
  39. YY1 modulates the radiosensitivity of esophageal squamous cell carcinoma through KIF3B-mediated Hippo signaling pathway.2023Cell death & disease免费全文
  40. Early detection of radiation-induced myocardial damage by [18F]AlF-NOTA-FAPI-04 PET/CT imaging.2023European journal of nuclear medicine and molecular imaging
  41. 18F-FAPI-04 PET/CT parameters predict PD-L1 expression in esophageal squamous cell carcinoma.2023Frontiers in immunology免费全文
  42. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.2023Frontiers in immunology免费全文
  43. Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma.2023Frontiers in immunology免费全文
  44. Integrating Preoperative Computed Tomography and Clinical Factors for Lymph Node Metastasis Prediction in Esophageal Squamous Cell Carcinoma by Feature-Wise Attentional Graph Neural Network.2023International journal of radiation oncology, biology, physics
  45. Clinical Outcome-Related Cancer Pathways and Mutational Signatures in Patients With Unresectable Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy.2023International journal of radiation oncology, biology, physics
  46. Do higher radiation doses improve survival for cervical esophageal squamous cell cancer patients treated with definitive chemoradiotherapy using intensity-modulated radiotherapy? A propensity-score matched analysis.2023Journal of cancer research and therapeutics
  47. The prognostic value of 11th Japanese classification and 8th AJCC staging systems in Chinese patients with esophageal squamous cell carcinoma.2023Journal of cardiothoracic surgery免费全文
  48. Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy.2023Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  49. Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report.2023Medicine免费全文
  50. Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy.2022BMC gastroenterology免费全文
  51. MiR-26b-5p in small extracellular vesicles derived from dying tumor cells after irradiation enhances the metastasis promoting microenvironment in esophageal squamous cell carcinoma.2022Cancer letters
  52. Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  53. Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma.2022International immunopharmacology
  54. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial.2022International journal of cancerRCT
  55. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.2022Journal of cancer research and therapeutics
  56. Integrated cohort of esophageal squamous cell cancer reveals genomic features underlying clinical characteristics.2022Nature communications免费全文
  57. The Hu antigen R/interferon-β axis modulates sensitivity of esophageal squamous cancer cells to cisplatin.2022Neoplasma
  58. Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures.2022Radiation oncology (London, England)RCT免费全文
  59. Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.2021Cancer medicine免费全文
  60. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.2021International immunopharmacology
  61. 3D Deep Learning Model for the Pretreatment Evaluation of Treatment Response in Esophageal Carcinoma: A Prospective Study (ChiCTR2000039279).2021International journal of radiation oncology, biology, physics
  62. Multiregion sequencing and subclonal analysis reveal intratumoral heterogeneity in esophageal squamous cell carcinoma.2021Journal of cancer research and therapeutics
  63. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis.2021Journal of translational medicine免费全文
  64. Oncogenic SNORD12B activates the AKT-mTOR-4EBP1 signaling in esophageal squamous cell carcinoma via nucleus partitioning of PP-1α.2021Oncogene
  65. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.2021Radiation oncology (London, England)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.状态不明NCT05323890牵头方II期2022-04 启动
  2. A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC已终止NCT02721550牵头方IV期2016-08 启动
  3. A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC已终止NCT02721576牵头方IV期2016-07 启动
  4. A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC已完成NCT02721563牵头方IV期2016-02 启动
  5. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186牵头方III期2015-03 启动
  6. Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma已完成NCT00815308牵头方II期2009-01 启动
  7. IMRT/Pemetrexed/Cisplatin in Esophageal Cancer状态不明NCT01630174牵头方2009-10 启动
  8. Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors邀请入组NCT06690216牵头方(推断)I/II期2024-03 启动
  9. A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy正在招募NCT06769113研究中心II期2025-01 启动
  10. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  11. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  12. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  13. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC状态不明NCT05221658研究中心II期2022-08 启动
  14. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  15. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  16. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  17. Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).状态不明NCT04063683研究中心II期2019-10 启动
  18. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  19. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  20. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  21. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  22. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
PubMed 以外找到的论文(未计入)87
  1. 2124P Sintilimab plus chemoradiotherapy as first-line treatment for stage IV ESCC with non-regional node metastases only: A phase II clinical trial2025Annals of Oncology论文
  2. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncology论文
  3. A Comparative Study of Automated and Manual Contouring in Radiomic Models for Lymph Node Assessment in Esophageal Squamous Cell Carcinoma2025International Journal of Radiation Oncology*Biology*Physics论文
  4. Combined PD-L1 expression and PD-1+ CD8 T cells to predict immunotherapy outcomes in esophageal squamous cell carcinoma.2025Journal of Clinical Oncology会议摘要
  5. Effects of lymphatic ablation approaches on immunotherapy efficacy in esophageal squamous cell carcinoma.2025Journal of Clinical Oncology论文
  6. Failure patterns and the value of postoperative adjuvant radiotherapy in esophageal squamous cell carcinoma patients treated with neoadjuvant immunotherapy combined with chemotherapy.2025Journal of Clinical Oncology论文
  7. Identifying Risk Factors and Evaluating Therapeutic Interventions for Anastomotic Recurrence in Postoperative Esophageal Squamous Cell Carcinoma2025International Journal of Radiation Oncology*Biology*Physics论文
  8. Impact of Muscle Mass Loss on Survival during Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center Retrospective Study in China (TIMES Study)2025International Journal of Radiation Oncology*Biology*Physics论文
  9. Impact of muscle mass loss on survival during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma: A multi-center retrospective study in China (TIMES study).2025Journal of Clinical Oncology论文
  10. Knockdown of DNAJC12 slows tumor progression and affects tumor radiosensitivity in esophageal squamous cell carcinoma2025Molecular & cellular biomechanics论文
  11. Nasal cavity and brain metastases from esophageal carcinoma detected by 68 Ga-FAPI PET/CT2025Journal of Nuclear Medicine and Molecular Imaging论文
  12. Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.2025Journal of Clinical Oncology会议摘要
  13. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncology论文
  14. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncology会议摘要
  15. Quantitative Parameters Derived from Dual Energy CT and Hematological Features Predict Pathological Complete Response in Neoadjuvant Chemoradiotherapy Esophageal Squamous Cell Carcinoma Patients2025International Journal of Radiation Oncology*Biology*Physics论文
  16. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A real-world study.2025Journal of Clinical Oncology论文
  17. The role of ADAR1-mediated A-to-I RNA editing and non-editing functions in radioresistance of esophageal squamous cell carcinoma.2025Journal of Clinical Oncology论文
  18. Tumor location affects the outcome of radiation therapy for esophageal squamous cell carcinoma: A Retrospective Study, Systematic Review, and Meta-analysis2025Research Square预印本
  19. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncology论文
  20. 1452P Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial2024Annals of Oncology论文
  21. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncology论文
  22. A-to-I RNA Editing of C16orf46 and Radiation Resistance by Regulating Cell Cycle Arrest and Apoptosis in Esophageal Cancer2024International Journal of Radiation Oncology*Biology*Physics论文
  23. Abstract 2876: Spatial immune cell atlas predicts the sensitivity to neoadjuvant PD-1 blockade treatment combined with radiotherapy in resectable esophageal squamous cell carcinoma2024Cancer Research会议摘要
  24. Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1st-RT): A single-arm, open-label, phase 2 trial.2024Journal of Clinical Oncology会议摘要
  25. Dual-Omics Combined Hematological Parameters Model Predicts Pathological Complete Response in Esophageal Squamous Cell Carcinoma Patients after Neoadjuvant Chemoradiotherapy:A Multicenter Study2024SSRN Electronic Journal预印本
  26. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.2024Journal of Clinical Oncology会议摘要
  27. ITGA5 and Radioresistance through DNA Damage Repair in Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  28. Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study2024International Journal of Radiation Oncology*Biology*Physics论文
  29. Longitudinal evaluation of circulating tumor cells in operable locally advanced esophageal squamous cell carcinoma2024Research Square预印本
  30. Neoadjuvant Tislelizumab Combined with Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Study and Exploration of Immunologic Features2024International Journal of Radiation Oncology*Biology*Physics论文
  31. Pathologic Response Prediction Value of18f-Fapi PET/CT in ESCC Treated with Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial2024International Journal of Radiation Oncology*Biology*Physics论文
  32. Pathological Response and Survival Outcome after Neoadjuvant Chemoradiotherapy vs. Immunochemotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  33. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncology会议摘要
  34. Revolutionizing outcome prediction for immunotherapy with vision transformer-based pathomics signature in esophageal squamous cell cancer.2024Journal of Clinical Oncology会议摘要
  35. Safety and Efficacy of Neoadjuvant Chemoradiotherapy with Concurrent Weekly Versus Tri-Weekly Cisplatin/Nab-Paclitaxel in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  36. SnoRNAs and Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  37. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncology论文
  38. 95P A single-arm, multicenter phase II trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)2023Immuno-Oncology Technology论文
  39. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  40. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Research会议摘要
  41. CT-Based Radiomics Combined with Genomics may Predict Survival in Esophageal Cancer Patients Receiving Definitive Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physics论文
  42. Development and Validation of a Radiomics-Based Model to Predict Overall Survival after Definitive Chemoradiotherapy in Patients with Esophageal Cancer2023International Journal of Radiation Oncology*Biology*Physics论文
  43. Effect of Histopathological Regression of Tumor and Lymph Node on the Progression of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physics论文
  44. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncology会议摘要
  45. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  46. Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.2023Journal of Clinical Oncology会议摘要
  47. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  48. Optimizing Disease-Free Survival Prognosis: The Tumor Regression Grade Combined with Post-Neoadjuvant Pathologic Lymph Node Category (TRG -ypN) Novel Staging Approach Post-Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esop2023SSRN Electronic Journal预印本
  49. Predicting Radiation Esophagitis using 18F-FAPI-04 PET/CT in Patients with LA-ESCC Treated with Concurrent Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physics论文
  50. Study on the Dynamic Changes of Myocardial Injury Markers in Radiotherapy for Esophageal Carcinoma and Its Correlation with Cardiac Dosimetry2023International Journal of Radiation Oncology*Biology*Physics论文
  51. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.2023Journal of Clinical Oncology会议摘要
  52. The Role of CT-Based Radiomics Nomogram in Differential Diagnosis of Immune Checkpoint Inhibitor-Related Pneumonitis from Radiation Pneumonitis for Patients with ESCC2023International Journal of Radiation Oncology*Biology*Physics论文
  53. Treatment Response Prediction Using a Combination of Hematological Biomarkers and CT Deep Learning Radiomics in Locally Advanced Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  54. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncology会议摘要
  55. 105P Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study2022Immuno-Oncology Technology论文
  56. 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial2022Immuno-Oncology Technology论文
  57. Abstract 6270: Integrating spatial transcriptomics and single-cell RNA-seq reveal the tumorigenesis and heterogeneity of esophageal squamous cell carcinoma2022Cancer Research会议摘要
  58. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  59. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  60. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  61. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  62. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  63. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  64. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  65. CT-Based Deep Learning Model for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Patients Received Concurrent Chemo-Radiotherapy: A Multicenter Study2022International Journal of Radiation Oncology*Biology*Physics论文
  66. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  67. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  68. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figshare数据集
  69. Sintilimab after Concurrent Chemoradiotherapy in Locoregional Recurrent ESCC after Definitive Treatment: A Single-Arm, Phase II Study2022International Journal of Radiation Oncology*Biology*Physics论文
  70. Two-Stage Phase II Study of Envafolimab Combined with Endostar and Concurrent Chemoradiotherapy in Treatment of Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Results of Stage 12022International Journal of Radiation Oncology*Biology*Physics论文
  71. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2022Journal of Clinical Oncology会议摘要
  72. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  73. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  74. Co-graph Attention Reasoning Based Imaging and Clinical Features Integration for Lymph Node Metastasis Prediction2021Lecture notes in computer science会议论文
  75. Corrigendum: Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients2021Frontiers in Oncology勘误
  76. Genomic Profiling Identified Prognostic Biomarkers of Definitive Chemo-Radiotherapy Response in Esophageal Carcinoma2021International Journal of Radiation Oncology*Biology*Physics论文
  77. IDDF2021-ABS-0158 Small extracellular vesicles derived from esophageal squamous cell carcinoma promote immunosuppressive effects of myeloid-derived suppressor cells after ionizing radiation2021Gut会议论文
  78. Improved lymph node metastasis prediction from preoperative esophageal squamous cell cancer CT by graph attention convolutional neural network (GACNN).2021Journal of Clinical Oncology会议摘要
  79. Integrating Preoperative CT and Clinical Factors for Lymph Node Metastasis Prediction in Esophageal Cancer by Feature-Wise Attentional Graph Neural Network (FAGNN)2021International Journal of Radiation Oncology*Biology*Physics论文
  80. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncology会议摘要
  81. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  82. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  83. Nomograms Predicting Response and Survival of Esophageal Squamous Cell Carcinoma Patients Treated With Anti-PD-1 Therapy2021International Journal of Radiation Oncology*Biology*Physics论文
  84. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要
  85. The Predictive Value of Tumor Volume, Inflammatory Biomarkers, and Their Dynamic Changes on Early Tumor Response for Elderly Patients With Esophageal Squamous Cell Carcinoma Underwent Radiotherapy2021Research Square预印本
  86. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncology会议摘要
  87. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.4%。

牵头论文
59
2021–2025 年
牵头试验
10
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 8820222023: 131320232024: 131320242025: 16162025

济南有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
    分期
    III期
    开始
    2025-07
    登记号
    NCT06841172

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  2. 正在招募
    BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
    分期
    II期
    开始
    2025-07
    登记号
    NCT07062055

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  3. 正在招募
    Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
    分期
    II期
    开始
    2023-10
    登记号
    NCT06904014

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  4. 即将招募
    Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
    分期
    II期
    开始
    2025-12
    登记号
    NCT07352007

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  5. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  6. 正在招募
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2025-08
    登记号
    NCT07391839

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、南京、合肥、广州、杭州、济南、福州、郑州

  7. 正在招募
    A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06530251

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、济南

  8. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题局部治疗(消融、TACE、HAIC)复发与预后免疫与靶向药物
论文中的科室放疗科肿瘤内科影像/核医学科普外/肝胆胰外科
牵头的论文59
  1. Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study.2026Hepatology international
  2. Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium.2025Academic radiology
  3. H3K36me3-Guided m6A Modification of Oncogenic L1CAM-AS1 Drives Macrophage Polarization and Immunotherapy Resistance in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Oncogenic RBM19 modulated by MAX-mediated allelic transcription regulation in hepatocellular carcinoma progression.2025Archives of biochemistry and biophysics
  5. Integrated functional genomics-identified LYRM4 promotes fumarate accumulation and hepatocellular carcinoma progression.2025Archives of biochemistry and biophysics
  6. Curcumin induces ferroptosis in hepatocellular carcinoma by regulating the P62-KEAP1-NRF2-signaling pathway.2025BMC cancer免费全文
  7. Clinical efficacy of TACE using coil or gelatin sponge combined with targeted therapy in the treatment of giant hepatocellular carcinoma with arterioportal fistulas.2025BMC gastroenterology免费全文
  8. Integrated functional genomics-identified DEAF1 in oxidative stress and hepatocellular carcinoma development.2025Carcinogenesis
  9. Impact of microwave ablation on survival rates and recurrence in hepatic malignant tumors.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  10. Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.2025Clinical and experimental medicine免费全文
  11. HCC-derived CX3CL1 affects hepatocellular carcinoma prognosis and CX3CR1 + MDSC infiltration.2025European journal of medical research免费全文
  12. C-reactive protein flare: a promising prognostic predictor for patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and immune checkpoint inhibitors.2025Frontiers in immunology免费全文
  13. Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.2025Frontiers in immunology免费全文
  14. CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study.2025Hepatology international
  15. Maintaining First-Line Therapy Plus Radiation Therapy May Prolong Progression-Free Survival and Delay Second-Line Therapy for Oligoprogressive Hepatocellular Carcinoma.2025International journal of radiation oncology, biology, physics
  16. Targeting NOTCH1-KEAP1 axis retards chronic liver injury and liver cancer progression via regulating stabilization of NRF2.2025Journal of experimental & clinical cancer research : CR免费全文
  17. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.2025Journal of hepatology
  18. Genome-wide functional integration identified MAZ-controlled RPS14 dysregulation in hepatocellular carcinoma.2024Archives of toxicology
  19. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.2024BMC cancer免费全文
  20. Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.2024BMC cancer免费全文
  21. Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years.2024BMC gastroenterology免费全文
  22. Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.2024Biochimica et biophysica acta. Reviews on cancer
  23. Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based study.2024British journal of cancer免费全文
  24. Expression and clinical significance of NLRC5 in hepatocellular carcinoma.2024Cancer biology & therapy免费全文
  25. CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib.2024Cancer medicine免费全文
  26. Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients.2024Frontiers in immunology免费全文
  27. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma.2024International journal of biological macromolecules
  28. Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study.2024Journal of cancer research and therapeutics
  29. Systemic Chemotherapy with or without Hepatic Arterial Infusion Chemotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Oligometastasis: A Propensity Score-Matched Analysis.2024Journal of vascular and interventional radiology : JVIR
  30. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.2024Nature communications免费全文
  31. Epirubicin may enhance the inhibition of hepatocellular carcinoma induced by iodine-125 seeds through downregulating WNT pathway.2023Asia-Pacific journal of clinical oncology
  32. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.2023BMC cancer免费全文
  33. Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients.2023BMC cancer免费全文
  34. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.2023BMC gastroenterology免费全文
  35. Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma.2023Cancer immunology, immunotherapy : CII免费全文
  36. Super Enhancer-Regulated LncRNA LINC01089 Induces Alternative Splicing of DIAPH3 to Drive Hepatocellular Carcinoma Metastasis.2023Cancer research
  37. Matrix metalloproteinase gene mutations and bioinformatics of telocytes in hepatocellular carcinoma.2023Cell biology international
  38. Tumour-derived exosomal lncRNA SNHG16 induces telocytes to promote metastasis of hepatocellular carcinoma via the miR-942-3p/MMP9 axis.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  39. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.2023Frontiers in immunology免费全文
  40. Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma.2023Hepatology international
  41. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.2023Journal of cancer research and therapeutics
  42. Characterization of disease-associated microbiota in hepatocellular carcinoma.2023Journal of cancer research and therapeutics
  43. Effect of type 2 diabetes on liver images of GD-EOB-DTPA-enhanced MRI during the hepatobiliary phase.2023Scientific reports免费全文
  44. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.2022BMJ open免费全文
  45. N6 -methyladenosine-modified lncRNA ARHGAP5-AS1 stabilises CSDE1 and coordinates oncogenic RNA regulons in hepatocellular carcinoma.2022Clinical and translational medicine免费全文
  46. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.2022European journal of pharmacology
  47. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.2022Frontiers in endocrinology免费全文
  48. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs.2022Frontiers in immunology免费全文
  49. Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors.2022Journal of immunology research免费全文
  50. Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study.2022Medicine免费全文
  51. Identifying a Novel Endoplasmic Reticulum-Related Prognostic Model for Hepatocellular Carcinomas.2022Oxidative medicine and cellular longevity免费全文
  52. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.2021Archives of toxicology
  53. N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization.2021Archives of toxicology
  54. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1.2021BMC cancer免费全文
  55. A preliminary investigation of re-evaluating the irradiation dose in hepatocellular carcinoma radiotherapy applying 4D CT and deformable registration.2021Journal of applied clinical medical physics免费全文
  56. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.2021Journal of cancer research and therapeutics
  57. Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  58. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.2021Medicine免费全文
  59. Serum-derived exosomes function as tumor antigens in patients with advanced hepatocellular carcinoma.2021Molecular immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
  1. Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC正在招募NCT06841172牵头方III期2025-07 启动
  2. BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases正在招募NCT07062055牵头方II期2025-07 启动
  3. SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma已暂停NCT07274774牵头方II期2025-11 启动
  4. Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer已完成NCT06261047牵头方2024-03 启动
  5. A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma状态不明NCT05185531牵头方I期2022-03 启动
  6. A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma已完成NCT05099848牵头方II期2021-03 启动
  7. Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma状态不明NCT01556815牵头方II期2012-05 启动
  8. TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma状态不明NCT01605734牵头方II期2012-07 启动
  9. Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular即将招募NCT07352007牵头方(推断)II期2025-12 启动
  10. Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC正在招募NCT06904014牵头方(推断)II期2023-10 启动
  11. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.正在招募NCT07391839研究中心I期2025-08 启动
  12. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  13. A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)正在招募NCT06530251研究中心I/II期2024-09 启动
  14. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  15. A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC进行中,不再招募NCT05319431研究中心II期2022-06 启动
  16. Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients进行中,不再招募NCT05377034研究中心II期2022-10 启动
  17. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  18. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  19. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 33 篇,占 0.3%。

牵头论文
33
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 8820232024: 7720242025: 13132025

济南有 7 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
    分期
    II期
    开始
    2025-10
    登记号
    NCT07007182

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  2. 正在招募
    Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
    分期
    II期
    开始
    2024-07
    登记号
    NCT07309185

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  3. 正在招募
    Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
    分期
    II期
    开始
    2021-03
    登记号
    NCT07320586

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省肿瘤医院济南

  4. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  5. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  6. 正在招募
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    分期
    I期
    开始
    2025-02
    登记号
    NCT06873659

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、兰州、北京、南京、广州、杭州、济南、西安

  7. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  8. 正在招募
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    II期
    开始
    2023-11
    登记号
    NCT06155383

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州

  9. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题化疗与综合治疗免疫与靶向药物营养与康复
论文中的科室放疗科肿瘤内科消化/肝病科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文33
  1. Overcoming Photothermal Resistance of Gastric Cancer by Bionic 2D Iron-Based Nanoplatforms with Precise CRISPR/Cas9 Delivery.2025ACS nano
  2. Machine learning-based integration develops a disulfidptosis-related lncRNA signature for improving outcomes in gastric cancer.2025Artificial cells, nanomedicine, and biotechnology
  3. Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review.2025Current cancer drug targets
  4. Improved Sampling Method to Enhance the Positive Rate of HER2 Detection in Gastric Cancer.2025Discovery medicine
  5. Exploring the possible mechanism of low-dose naloxone exposure improving the immune microenvironment of gastric cancer tumors.2025Frontiers in immunology免费全文
  6. GABRD Accelerates Tumour Progression via Regulating CCND1 Signalling Pathway in Gastric Cancer.2025Journal of cellular and molecular medicine免费全文
  7. Single-cell RNA Sequencing Analysis Reveals Cancer-associated Fibroblast Signature for Prediction of Clinical Outcomes and Immunotherapy in Gastric Cancer.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  8. Key Lipid Reprogramming Revealed in Gastric Signet Ring Cell Carcinoma by Spatial Mass Spectrometry Metabolomics.2025Journal of the American Society for Mass Spectrometry
  9. Non-coding RNAs in gastric cancer: mechanisms and therapeutic prospects.2025Molecular cancer免费全文
  10. METTL3 Promotes Gastric Cancer Progression via Modulation of FNTA-Mediated KRAS/ERK Signaling Activation.2025Molecular cancer research : MCR
  11. Regulatory mechanisms of the Hippo/YAP axis by G-protein coupled estrogen receptor in gastric signet-ring cell carcinoma.2025Neoplasia (New York, N.Y.)免费全文
  12. Patterns of Recurrence After D2 Radical Surgery for Gastric Cancer: Implications for Postoperative Radiation Therapy.2025Practical radiation oncology
  13. Oxaliplatin accelerates immunogenic cell death by activating the cGAS/STING/TBK1/IRF5 pathway in gastric cancer.2025The FEBS journal
  14. Effects of perioperative low-dose naloxone on the immune system in patients undergoing laparoscopic-assisted total gastrectomy: a randomized controlled trial.2024BMC anesthesiologyRCT免费全文
  15. Overall and cause-specific mortality among patients diagnosed with gastric precancerous lesions in Sweden between 1979 and 2014: an observational cohort study.2024BMC medicine免费全文
  16. Study on correlation between perioperative cognitive function and nutritional status in elderly patients with gastric cancer.2024Experimental gerontology
  17. Super-enhancers: Implications in gastric cancer.2024Mutation research. Reviews in mutation research
  18. KBTBD2 promotes proliferation and migration of gastric cancer via activating EGFR signaling pathway.2024Pathology, research and practice
  19. Acyltransferase zinc finger DHHC-type containing 2 aggravates gastric carcinoma growth by targeting Nrf2 signaling: A mechanism-based multicombination bionic nano-drug therapy.2024Redox biology免费全文
  20. Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study.2024Science progress免费全文
  21. LINC01226 promotes gastric cancer progression through enhancing cytoplasm-to-nucleus translocation of STIP1 and stabilizing β-catenin protein.2023Cancer letters
  22. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.2023Cancer medicine免费全文
  23. CircPDIA4 Induces Gastric Cancer Progression by Promoting ERK1/2 Activation and Enhancing Biogenesis of Oncogenic circRNAs.2023Cancer research
  24. Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer.2023Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  25. OASL knockdown inhibits the progression of stomach adenocarcinoma by regulating the mTORC1 signaling pathway.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  26. LINC00240 in the 6p22.1 risk locus promotes gastric cancer progression through USP10-mediated DDX21 stabilization.2023Journal of experimental & clinical cancer research : CR免费全文
  27. Single-cell analysis of gastric signet ring cell carcinoma reveals cytological and immune microenvironment features.2023Nature communications免费全文
  28. The ASH1L-AS1-ASH1L axis controls NME1-mediated activation of the RAS signaling in gastric cancer.2023Oncogene
  29. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.2022Frontiers in immunology免费全文
  30. Construction of a Cuprotosis-Related Gene-Based Model to Improve the Prognostic Evaluation of Patients with Gastric Cancer.2022Journal of immunology research免费全文
  31. Effect of LAMA4 on Prognosis and Its Correlation with Immune Infiltration in Gastric Cancer.2021BioMed research international免费全文
  32. LncPSCA in the 8q24.3 risk locus drives gastric cancer through destabilizing DDX5.2021EMBO reports免费全文
  33. Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
中文论文(未计入)1
  1. [Perioperative radiotherapy on local-advanced gastric cancer--From the perspective of failure pattern].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
  1. Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy正在招募NCT07309185牵头方II期2024-07 启动
  2. Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer正在招募NCT07320586牵头方II期2021-03 启动
  3. The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.已完成NCT03384511牵头方IV期2016-09 启动
  4. Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer正在招募NCT07007182牵头方(推断)II期2025-10 启动
  5. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  6. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  7. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors正在招募NCT06873659研究中心I期2025-02 启动
  8. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  9. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06155383研究中心II期2023-11 启动
  10. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  11. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.进行中,不再招募NCT06116136研究中心I/II期2024-08 启动
  12. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors已完成NCT05253053研究中心I/II期2022-04 启动
  13. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  14. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.已终止NCT05188209研究中心II期2021-12 启动
  15. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  16. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  17. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  18. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  19. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  20. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  21. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer已完成NCT03427814研究中心II期2018-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 4 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 8 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

济南有 18 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文1
  1. Identification of Prognostic RBPs in Osteosarcoma.2021Technology in cancer research & treatment
早期论文(2016–2020 年)2
  1. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. Serum CEACAM1 Level Is Associated with Diagnosis and Prognosis in Patients with Osteosarcoma.2016PloS one

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

济南有 4 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

济南有 8 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
    分期
    I期
    开始
    2022-12
    登记号
    NCT05562024

    年龄 1 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心天津、济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

济南有 5 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
    分期
    I期
    开始
    2024-03
    登记号
    NCT06340204

    年龄 8 岁 至 40 岁(登记的条件)

    牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma正在招募NCT06340204研究中心I期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

济南有 7 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-06
    登记号
    NCT06574568

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州

  2. 正在招募
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    分期
    II期
    开始
    2022-04
    登记号
    NCT05294055

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州

  3. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植肾脏与骨骼并发症
论文中的科室肿瘤内科放疗科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 8 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室放疗科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

山东省肿瘤医院

Shandong Cancer Hospital and Institute

济南

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Shandong Cancer Hospital; Shandong Cancer Hospital Affiliated to Shandong University; Shandong University Cancer Center; Shandong Cancer Hospital & Institute; Shandong Cancer Hospital And Institute; Shandong Cancer Hospital affiliated to Shandong University Jinan; Shandong Cancer Hospital Affiliated to Shandong University of Jinan; Shandong Cancer Hospital and Institute (HL)

提出更正下载数据